Creative Planning Purchases New Position in Cryolife Inc (NYSE:CRY)

Creative Planning purchased a new stake in shares of Cryolife Inc (NYSE:CRY) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 7,706 shares of the medical equipment provider’s stock, valued at approximately $209,000.

Several other institutional investors also recently made changes to their positions in CRY. Tower Research Capital LLC TRC grew its holdings in shares of Cryolife by 357.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,285 shares of the medical equipment provider’s stock valued at $62,000 after purchasing an additional 1,785 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Cryolife during the 4th quarter valued at approximately $87,000. SG Americas Securities LLC bought a new stake in shares of Cryolife during the 4th quarter valued at approximately $116,000. Mackay Shields LLC acquired a new stake in Cryolife during the 3rd quarter worth approximately $279,000. Finally, Municipal Employees Retirement System of Michigan boosted its position in Cryolife by 10.9% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 11,250 shares of the medical equipment provider’s stock worth $305,000 after buying an additional 1,110 shares during the period. 76.75% of the stock is currently owned by institutional investors.

Several equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Cryolife from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. ValuEngine downgraded shares of Cryolife from a “buy” rating to a “hold” rating in a research report on Saturday, January 4th. Needham & Company LLC lifted their target price on shares of Cryolife from $30.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. First Analysis downgraded shares of Cryolife from a “strong-buy” rating to an “outperform” rating in a research report on Friday. Finally, Oppenheimer assumed coverage on shares of Cryolife in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $34.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cryolife presently has an average rating of “Buy” and a consensus price target of $32.00.

In related news, Director Ronald D. Mccall sold 4,000 shares of Cryolife stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $24.56, for a total transaction of $98,240.00. Also, VP Jean F. Holloway sold 8,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $30.00, for a total transaction of $253,740.00. Following the completion of the transaction, the vice president now owns 67,322 shares in the company, valued at approximately $2,019,660. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,837 shares of company stock worth $536,927. 4.40% of the stock is owned by corporate insiders.

NYSE:CRY opened at $27.53 on Friday. The firm’s 50 day simple moving average is $29.08 and its 200 day simple moving average is $26.60. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.03 and a quick ratio of 3.82. Cryolife Inc has a one year low of $20.76 and a one year high of $33.00. The company has a market cap of $1.03 billion, a PE ratio of 688.42, a P/E/G ratio of 43.91 and a beta of 0.67.

Cryolife (NYSE:CRY) last posted its earnings results on Thursday, February 13th. The medical equipment provider reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. Cryolife had a net margin of 0.62% and a return on equity of 4.19%. The business had revenue of $69.70 million for the quarter, compared to the consensus estimate of $72.95 million. Equities research analysts expect that Cryolife Inc will post 0.34 EPS for the current year.

Cryolife Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Market Indexes

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.